Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Kopran has informed that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday 27th May, 2022, to consider and approve and take on record the following: Standalone and Consolidated Audited Financial Result of the Company for the Quarter and Financial Year ended March 31, 2022, and recommend Dividend (if any). Further, pursuant to the Company's Code of Conduct for Regulating & Reporting of Trading by Insiders and for Fair Disclosure, the 'Trading Window' for dealing in the securities of the Company which was closed from 1st April, 2022, will re-open 48 hours after the declaration of the financial results.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: